Entering a target dose of 4,000mcg shows a draw volume of 0.4mL, or 40 units on a U-100 syringe
Early animal studies published in the *Journal of Endocrinology* showed that AOD-9604 could stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat creation) in obese Zucker rats
Studies suggest that AOD 9604 has a favorable safety profile, especially when compared to full-form growth hormone treatments
The cost of such treatments is shaped by quality, regulatory status, supplier reputation, and formulation
Specifications for purity, identity, bond integrity, and endotoxin are committed in writing before each synthesis run, which keeps release decisions tied to measured chemistry
The 2.5mg dose is the standard starting dose for tirzepatide